D&DIAGNOSIS & EARLY DETECTION
Diagnosis & Early Detection/November 19, 2026/3 min read

Could New Guidelines Change How We Treat Low Blood Sugar in Kids Using Insulin Pumps?

Researchers are testing whether updated treatment thresholds for low blood sugar work safely for children and young adults using automated insulin delivery systems. A new clinical trial aims to find out if these revised guidelines could reduce unnecessary treatment while keeping kids safe.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

diagnosisscreeningautoantibodiesstaging

Key takeaways

  • Current hypoglycemia guidelines recommend treating blood sugar below 3.9 mmol/L, but these were created before automated insulin pumps became common
  • A new trial will test whether a slightly lower treatment threshold (3.6 mmol/L or below) works just as safely for young people on insulin pumps
  • The revised approach also considers real-time trends from continuous glucose monitors, active insulin, exercise, and symptoms—not just the number itself
  • Researchers want to make sure any new guidelines don't increase time spent in dangerously low blood sugar

Why Guidelines Might Need an Update

For decades, doctors have used the same hypoglycemia treatment guideline: start treatment when blood glucose falls below 3.9 mmol/L (about 70 mg/dL). This threshold was developed to keep people safe from severe low blood sugar and its complications.

But medicine has changed. Many young people now use automated insulin delivery (AID) systems—also called artificial pancreas technology—which constantly monitor blood sugar and adjust insulin doses automatically. These systems work very differently than the older insulin pumps and multiple daily injections that were common when current guidelines were written.

Because these technologies can catch and prevent many low blood sugar episodes before they become dangerous, some experts wonder if the old threshold still makes sense for people using them.

What This New Trial Will Study

Researchers at a single center are launching a study with 45 young people ages 6 to 25 who have had Type 1 diabetes for at least 12 months and use automated insulin delivery systems.

Each participant will try two different approaches for managing low blood sugar, one at a time. The standard approach follows current guidelines: treat when glucose drops below 3.9 mmol/L. The revised approach would treat at 3.6 mmol/L or below—but it goes further by also looking at the direction the blood sugar is heading (from continuous glucose monitor trends), how much active insulin is in the body, whether the person is exercising, and any symptoms they're feeling.

Each treatment approach will last four weeks, with two weeks of a 'washout' period in between so the effects don't overlap.

What Researchers Will Measure

The main question: Does the revised approach keep young people safe? Researchers will carefully track the percentage of time spent in clinically significant hypoglycemia—blood sugar below 3.0 mmol/L—using continuous glucose monitors.

They'll also look at other important measures, like how much time participants spend in their target blood sugar range, how much time above range, and whether young people and families actually find the revised approach acceptable and usable in real life.

What This Could Mean

If the revised approach proves non-inferior (works just as safely and effectively), it could lead to updated clinical guidelines that better fit how modern insulin pumps actually work.

This research is early-stage and limited to one center, so results will need careful review before any changes to standard practice. For now, families should follow their healthcare team's current recommendations for their child's specific situation. Any changes to treatment thresholds or approaches should only come through discussions with their diabetes care team.

Evidence label

Source: Diabetic medicine : a journal of the British Diabetic Association. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.